

XX Sequence 25 AA;

Query Match
Best Local Similarity 100.0%; Score 132; DB 5; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NLMAAORYGRELRRMSDFVDSFKK 25
DB 1 NLMAAORYGRELRRMSDFVDSFKK 25

RESULT 2
ABP56161
ID ABP56161 standard; peptide; 25 AA.

AC ABP56161;
DT 28-MAR-2003 (first entry)
DE PTPC-interacting TOX peptide #27.

XX Mitochondrial membrane permeabilisation; mitochondrion; PTPC;
XX permeability transition pore complex; virotoxin; neuroprotective;
XX vasoregulatory; cytoskeletal; infection; cell death regulation; apoptosis;
XX mitochondrial permeability transition pore complex modulator; cancer;
XX apoptogenic; ischaemia; neurodegenerative disease; fulminant hepatitis.

OS Synthetic.

PN W0200261105-A2.

PD 08-AUG-2002.

PF 01-FEB-2002; 2002MO-EP001633.

PR 02-FEB-2001; 2001US-0265594P.

XX (INST) INST PASTEUR.

PA (CNRS) CENT NAT RECH SCI.

PI Edelman L, Jacotot E, Briand J;

DR WPI; 2002-619260/66.

XX New chimeric bifunctional molecules that target specific cells and
PT regulate the apoptosis function of the permeability transition pore
PT complex of the mitochondria, useful for treating or preventing e.g.
PT cancer or ischemia.

PS Claim 9; Page 11; 76pp; English.

The present invention describes a chimeric bifunctional molecule (1) comprising at least a first functional molecule covalently linked to a permeability transition pore complex (PTPC) of the mitochondria. (1) has population of specifically targeting and entering a tissue cell specifically targeting, and inducing or preventing the death of the cells by apoptosis by regulating the opening or the closing of the PTPC of the mitochondria or its fragment. (1) has virotoxin, neuroprotective, permeability transition pore complex (PTPC) modulator. (1) is useful for treating or preventing a pathological infection or disease. (1) is also useful for regulating cell death regulatory molecules, specifically the apoptogenic function of the PTPC, for treating e.g. cancer, ischaemia, neurodegenerative diseases, fulminant hepatitis or viral infections. The present sequence represents a PTPC-interacting TOX peptide which is given in the exemplification of the present invention

Sequence 25 AA;

Query Match 100.0%; Score 132; DB 5; Length 25;

Best Local Similarity 100.0%; Pred. No. 3.4e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NLMAAORYGRELRRMSDFVDSFKK 25
DB 1 NLMAAORYGRELRRMSDFVDSFKK 25

RESULT 3
AAU78610
ID AAU78610 standard; peptide; 25 AA.

AC AAU78610;
DT 18-JUN-2002 (first entry)

XX Human Bad peptide #10 which binds to a member of the Bcl-2 family.
XX Human; Bad; Bcl-2; apoptosis; cancer; inducer; degenerative disease;
XX ischemic injury; suppressor; BH3 domain.

OS Homo sapiens.

PN W0200220568-A2.

PD 14-MAR-2002.

PF 04-SEP-2001; 2001MO-US027410.

PR 06-SEP-2000; 2000US-00656399.

XX (ABBO) ABBOTT LAB.

PI Fesik SW, Meadows RP, Joseph MK, Olejniczak ET, Petros AM;
PI Necteshelm DG, Swift KM, Matayoshi E, Zhang H;

DR WPI; 2002-292254/33.

XX New derivatives of Bad peptide, useful for identifying compounds that
PT bind to Bcl-2 proteins, potential agents for treating cancer and
PT degenerative disease.

PS Claim 18; Page 18; 31pp; English.

The present invention relates to new peptides that are derived from a wild-type human Bad peptide and are able to bind to a member of the Bcl-2 protein family. The peptides are useful, when labelled, in competitive/displacement assays for identifying substances that bind to members of the Bcl-2 family and may induce or suppress apoptosis so are potentially useful for treating cancer (inducers) or degenerative diseases or ischemic injury (suppressors). The peptides of the invention have high helix propensity, maintain the contacts of the wild-type Bad peptide and, compared with the Bad peptide, may have better physical properties, particularly solubility. The present sequence represents one of a collection of Bad peptides (AAU78601-AAU78631) that were derived from the BH3 domain of the human wild-type Bad peptide

Sequence 25 AA;

Query Match 100.0%; Score 132; DB 5; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 NLMAAORYGRELRRMSDFVDSFKK 25
DB 1 NLMAAORYGRELRRMSDFVDSFKK 25

RESULT 4
ADK90776
ID ADK90776 standard; peptide; 25 AA.
XX ADK90776;

Seq 20 NO = 10
Exhib A

Ch4.123

RESULT 2
US-08-717-123-2
Sequence 2, Application US/0871123
Patent No. 5965703
GENERAL INFORMATION:
APPLICANT: Horne, William A.
APPLICANT: Oltersdorf, Tilmann
TITLE OF INVENTION: Human BAD Polypeptides, Encoding Nucleic
TITLE OF INVENTION: Acids and Methods of Use
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: United States
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/717,123
FILING DATE: 20-SRP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,815
REFERENCE/DOCKET NUMBER: P-ID 1929
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 168 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-717-123-2

Query Match 100.0%; Score 132; DB 1; Length 168;
Best Local Similarity 100.0%; Pred. No. 7.9e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NLMAAQRXGRLRMSDEFVDSFKK 25
DB 103 NLMAAQRXGRLRMSDEFVDSFKK 127

RESULT 3
US-08-985-335-1
Sequence 1, Application US/08985335
Patent No. 6080847
GENERAL INFORMATION:
APPLICANT: Hillman, Jennifer L.
APPLICANT: Yue, Henry
APPLICANT: Lal, Preeti
APPLICANT: Shah, Purvi
APPLICANT: Corley, Neil C.
TITLE OF INVENTION: PROTEINS ASSOCIATED WITH CELL
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Dr.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,335
FILING DATE: Filed Herewith
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0421 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 168 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: SYNORAB01
CLONE: 358673
US-08-985-335-1

Query Match 100.0%; Score 132; DB 2; Length 168;
Best Local Similarity 100.0%; Pred. No. 7.9e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NLMAAQRXGRLRMSDEFVDSFKK 25
DB 103 NLMAAQRXGRLRMSDEFVDSFKK 127

RESULT 4
US-08-985-335-7
Sequence 7, Application US/08985335
Patent No. 6080847
GENERAL INFORMATION:
APPLICANT: Hillman, Jennifer L.
APPLICANT: Yue, Henry
APPLICANT: Lal, Preeti
APPLICANT: Shah, Purvi
APPLICANT: Corley, Neil C.
TITLE OF INVENTION: PROTEINS ASSOCIATED WITH CELL
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Dr.
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,335
FILING DATE: Filed Herewith
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0421 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166